Global control of hepatitis B virus: Does treatment-induced antigenic change affect immunization?

Bulletin of the World Health Organization

Volumn 88, Issue 1, 2010, Pages 66-73

  Clements, C John ^a   Coghlan, Ben ^b   Creati, Mick ^b   Locarnini, Stephen ^c   Tedder, Richard S ^d   Torresi, Joseph ^e  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^c VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

^e AUSTIN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; MACROGOL; MEMBRANE ANTIGEN; TELBIVUDINE; TENOFOVIR;

ANTIGEN; CANCER; DISEASE CONTROL; DISEASE INCIDENCE; DRUG; HEALTH IMPACT; HEPATITIS; IMMUNIZATION; MUTATION; PROTEIN; VACCINE; VIRAL DISEASE;

GENE MUTATION; HEALTH HAZARD; HEPATITIS B; HUMAN; INFECTION CONTROL; MONOTHERAPY; MORBIDITY; PASSIVE IMMUNIZATION; PREVENTIVE HEALTH SERVICE; PROPHYLAXIS; REVIEW; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; GENOME, VIRAL; GENOTYPE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNIZATION PROGRAMS; MUTATION; WORLD HEALTH;

HEPATITIS B VIRUS;

EID: 74549149960     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.08.065722     Document Type: Review

References (51)

1. Kane M. Global status of hepatitis B immunization. Lancet 1997;350:1102. doi:10.1016/S0140-6736(05)70464-5 PMID:10213575
2. Hanson DL, Adjé-Touré C, Talla-Nzussouo N, Eby P, Borget MY, Ya Kouadio L, et al. HIV Type 1 drug resistance in adults receiving highly active antiretroviral therapy in Abidjan, Côte d'Ivoire. AIDS Res Hum Retroviruses 2009;25:489-95. doi:10.1089/aid.2008.0273 PMID:19388820
3. Okamoto H, Tsuda F, Sakugawa H, Sastrosoewignjo RI, Imai M, Miyakawa Y, et al. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol 1988;69:2575-83. doi:10.1099/0022-1317-69-10-2575 PMID:3171552
4. Lindh M, Andersson AS, Gusdal A. Genotypes, nt 1858 variants and geographic origin of hepatitis B virus large-scale analysis using a new genotyping method. J Infect Dis 1997;175:1285-93. PMID:9180165 doi:10.1086/516458
5. Magnius LO, Norder H. Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene. Intervirology 1995;38:24-34. PMID:8666521
6. Torresi J, Earnest-Silveira L, Civitico G, Walters T, Lewin SR, Fyfe J, et al. Restoration of replication phenotype of lamivudine resistant hepatitis B virus mutants by compensatory changes in the "fingers" sub-domain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology 2002;299:88-99. PMID:12167344 doi:10.1006/viro.2002.1448
7. Torresi J, Earnest-Silveira L, Deliyannis G, Edgtton K, Zhuang H, Locarnini SA, et al. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 2002;293:305-13. PMID:11886250 doi:10.1006/viro.2001.1246
8. Hessel L, West DJ. Antibody responses to recombinant hepatitis B vaccines. Vaccine 2002;20:2164-5. PMID:12009268 doi:10.1016/S0264- 410X(02)00117-2
9. Theamboonlers A, Chongsrisawat V, Jantaradsamee P, Poovorawan Y. Variants within the "a" determinant of HBs gene in children and adolescents with and without hepatitis B vaccination as part of Thailand's Expanded Program on Immunization (EPI). Tohoku J Exp Med 2001;193:197-205. PMID:11315767 doi:10.1620/tjem.193.197
10. He C, Nomura F, Itoga S, Isobe K, Nakai T. Prevalence of vaccine-induced escape mutants of hepatitis B virus in the adult population in China: a prospective study in 176 restaurant employees. J Gastroenterol Hepatol 2001;16:1373-7. PMID:11851835 doi:10.1046/j.1440-1746.2001.02654.x
11. Su FH, Chen JD, Cheng SH, Lin CH, Liu YH, Chu FY. Seroprevalence of Hepatitis-B infection amongst Taiwanese university students 18 years following the commencement of a national Hepatitis-B vaccination program. J Med Virol 2007;79:138-43. PMID:17177303 doi:10.1002/jmv.20771
12. Carman WF. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat 1997;4 Suppl 1;11-20. doi:10.1111/j.1365-2893.1997. tb00155.x PMID:9097273
13. Wands JR, Fujita YK, Isselbacher KJ, Degott C, Schellekens H, Dazza MC, et al. Identification and transmission of hepatitis B virus-related variants. Proc Natl Acad Sci USA 1986;83:6608-12. PMID:3462716 doi:10.1073/pnas.83. 17.6608
14. Karthigesu VD, Allison LM, Fortuin M, Mendy M, Whittle HC, Howard CR. A novel hepatitis B virus variant in the sera of immunized children. J Gen Virol 1994;75:443-8. PMID:8113769 doi:10.1099/0022-1317-75-2-443
15. Carman WF, Wallace L, Ward K, Hawkins A, Rice S, Tedder R. Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA. Lancet 1995;345:1406-7. PMID:7539089 doi:10.1016/S0140-6736(95)92599-6
16. Carman WF, Trautwein C, van Deursen FJ, Colman K, Dornan E, McIntyre G, et al. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology 1996;24:489-93. PMID:8781312 doi:10.1002/hep.510240304
17. Carman WF. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat 1997;4:11-20. PMID:9097273 doi:10.1111/j.1365-2893.1997.tb00155.x
18. Waters JA, Kennedy M, Voet P, Hauser P, Petre J, Carman W, et al. Loss of the common "a" determinant of hepatitis B surface antigen by a vaccine-induced escape mutant. J Clin Invest 1992;90:2543-7. PMID:1281839 doi:10.1172/JCI116148
19. Oon CJ, Lim GK, Ye Z, Goh KT, Tan KL, Yo SL, et al. Molecular epidemiology of hepatitis B virus vaccine variants in Singapore. Vaccine 1995;13:699-702. PMID:7483783 doi:10.1016/0264-410X(94)00080-7
20. Hsu HY, Chang MH, Liaw SH, Ni YH, Chen HL. Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. Hepatology 1999;30:1312-7. PMID:10534356 doi:10.1002/hep. 510300511
21. Karthigesu VD, Allison LM, Fortuin M, Mendy M, Whittle HC, Howard CR. A novel hepatitis B virus variant in the sera of immunized children. J Gen Virol 1994;75:443-8. PMID:8113769 doi:10.1099/0022-1317-75-2-443
22. Papaevangelou G, Dandolos E, Roumeliotou-Karayannis A, Richardson SC. Immunogenicity of recombinant hepatitis B vaccine. Lancet 1985;1:455-6. PMID:2857828 doi:10.1016/S0140-6736(85)91171-7
23. Stevens CE, Taylor PE, Tong MJ, Toy PT, Vyas GN, Nair PV, et al. Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA 1987;257:2612-6. PMID:2952812 doi:10.1001/jama.257.19.2612
24. Jilg W, Schmidt M, Deinhardt F. Prolonged immunity after late booster doses of hepatitis B vaccine. J Infect Dis 1988;157:1267-9. PMID:2967336
25. Basuni AA, Butterworth L, Cooksley G, Locarnini S, Carman WF. Prevalence of HBsAg mutants and impact of hepatitis B infant immunisation in four Pacific Island countries. Vaccine 2004;22:2791-9. PMID:15246613 doi:10.1016/j.vaccine.2004.01.046
26. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000;46:562-8 PMID:10716688
27. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-39. PMID:17256718 doi:10.1002/hep.21513
28. Thomas H, Foster G, Platis D. Mechanisms of action of interferon and nucleoside analogues. J Hepatol 2003;39 Suppl 1;93-8. PMID:14708685 doi:10.1016/S0168-8278(03)00207-1
29. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206-17. PMID:15371578 doi:10.1056/NEJMoa040431
30. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-95. PMID:15987917 doi:10.1056/NEJMoa043470
31. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000;46:562-8. PMID:10716688 doi:10.1136/gut.46.4.562
32. Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000;31:1318-26. PMID:10827158 doi:10.1053/jhep.2000.7296
33. Torresi J, Earnest-Silveira L, Civitico G, Walters T, Lewin SR, Fyfe J, et al. Restoration of replication phenotype of lamivudine resistant hepatitis B virus mutants by compensatory changes in the "fingers" sub-domain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology 2002;299:88-99. PMID:12167344 doi:10.1006/viro.2002.1448
34. Torresi J, Earnest-Silveira L, Deliyannis G, Edgtton K, Zhuang H, Locarnini SA, et al. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 2002;293:305-13. PMID:11886250 doi:10.1006/viro.2001.1246
35. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok ASF. Management of Hepatitis B: Summary of a Clinical Research Workshop. Hepatology 2007;45:1056-75. PMID:17393513 doi:10.1002/hep.21627
36. Thibault V, Aubron-Olivier C, Agut H, Katlama C. Primary infection with a lamivudine-resistant hepatitis B virus. AIDS 2002;16:131-3. PMID:11741175 doi:10.1097/00002030-200201040-00020
37. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123-9. PMID:15639293 doi:10.1016/S0140-6736(05)17701-0
38. Locarnini S, Hatzakis A, Heathcote J, Keeffe EB, Liang TJ, Mutimer D, et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 2004;9:679-93. PMID:15535405
39. Torresi J. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol 2002;25:97-106. doi:10.1016/S1386-6532(02)00049-5 PMID:12367644
40. Sheldon J, Soriano V. Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Chemother 2008;61:766-8. PMID:18218641 doi:10.1093/jac/dkn014
41. Papatheodoridis GV, Hadziyannis SJ. Review article: current management of chronic hepatitis B. Aliment Pharmacol Ther 2004;19:25-37. PMID:14687164 doi:10.1046/j.1365-2036.2003.01810.x
42. Sheldon J, Ramos B, Garcia-Samaniego J, Rios P, Bartholomeusz A, Romero M et al. Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV co-infected patients failing antiretroviral drugs with anti-HBV activity. J Acquir Immune Defic Syndr 2007;46:279-82. PMID:18167643 doi:10.1097/QAI.0b013e318154bd89
43. Fung SK, Lok AS. Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection? Hepatology 2004;40:790-2. PMID:15382157
44. Liu C-J, Kao J-H, Chen D-S. Therapeutic implications of hepatitis B virus genotypes. Liver Int 2005;25:1097-107. PMID:16343058 doi:10.1111/j.1478-3231.2005.01177.x
45. Toan NL, Song L, Kremsner PG, Duy D, Binh V, Koeberlein B, et al. Impact of the hepatitis B virus genotype and genotype-mixtures on the course of liver disease in Vietnam. Hepatology 2006;43:1375-84. PMID:16729315 doi:10.1002/hep.21188
46. Matthews GV, Bartholomeusz A, Locarnini S, Ayres A, Sasaduesz J, Seaberg E, et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 2006;20:863-70. PMID:16549970 doi:10.1097/01.aids. 0000218550.85081.59
47. Alter MJ. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol 2003;39: Suppl 1;64-9. PMID:14708680 doi:10.1016/S0168-8278(03) 00141-7
48. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al. Asian-Pacific consensus statement of the management of chronic hepatitis B: a 2008 update. Hepatology International 2008.
49. Proceedings of the European Association for the Study of the Liver (EASL) International Consensus Conference on Hepatitis B. 14-16 September, 2002. Geneva, Switzerland. J Hepatol 2003;39 Suppl 1;S1-235. PMID:14964189
50. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-39. PMID:17256718 doi:10.1002/hep.21513
51. Wilson JN, Nokes DJ, Carman WF. The predicted pattern of emergence of vaccine-resistant hepatitis B: a cause for concern? Vaccine 1999;17:973-8. PMID:10067705 doi:10.1016/S0264-410X(98)00313-2